Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …

Background Human papillomavirus (HPV) vaccination programmes were first implemented
in several countries worldwide in 2007. We did a systematic review and meta-analysis to …

Background The investigational 9-valent viruslike particle vaccine against human
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …

Objective To measure the effect on genital warts of the national human papillomavirus
vaccination programme in Australia, which started in mid-2007. Design Trend analysis of …

Background Australia was one of the first countries to introduce a publicly funded national
human papillomavirus (HPV) vaccination program that commenced in April 2007, using the …

Background The long-term effectiveness of the quadrivalent human papillomavirus (qHPV)
vaccine was assessed by monitoring the combined incidence of cervical intraepithelial …

Objective To quantify the effect on cervical disease at age 20 years of immunisation with
bivalent human papillomavirus (HPV) vaccine at age 12-13 years. Design Retrospective …

Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …

We reviewed intervention studies designed to increase human papillomavirus (HPV)
vaccination coverage to further understand the impact interventions can have on HPV …

Background In clinical trials, vaccines against human papillomavirus (HPV) have been
highly effective against HPV16-or HPV18-associated cervical lesions. The quadrivalent HPV …